Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.200
+0.010 (0.84%)
At close: Mar 9, 2026, 4:00 PM EDT
1.190
-0.010 (-0.83%)
After-hours: Mar 9, 2026, 7:14 PM EDT
Soligenix Revenue
In the year 2024, Soligenix had annual revenue of $119.37K, down -85.78%.
Revenue (ttm)
$119.37K
Revenue Growth
-85.78%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
12.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 12.74M |
| BioAtla | 11.00M |
| Traws Pharma | 2.85M |
| CytoMed Therapeutics | 573.19K |
| BioCardia | 3.00K |
SNGX News
- 11 days ago - Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease - PRNewsWire
- 13 days ago - Soligenix to Present at BIO Investment & Growth Summit - PRNewsWire
- 25 days ago - Soligenix Details Recent Progress and Upcoming Milestones - PRNewsWire
- 2 months ago - Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - PRNewsWire
- 2 months ago - Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
- 2 months ago - Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis - PRNewsWire
- 3 months ago - Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - GlobeNewsWire
- 3 months ago - Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire